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Abstract: Aim: The aim of this study was to perform a comprehensive meta-analysis of the association
between coffee consumption and risk of endometrial cancer. Methods: Eligible studies were identified
by searching the PubMed and EMBASE databases. The dose–response relationship as well as
the risk of endometrial cancer for the highest versus the lowest categories of coffee consumption
were assessed. Subgroup analyses considering the menopausal and receptor statuses, the smoking
status, and the BMI (Body Mass Index) were performed in order to identify potential confounders.
Results: We identified a total of 12 studies eligible for meta-analysis. A dose–response meta-analysis
showed a decreased risk of endometrial cancer. Moreover, a subgroup analysis indicated that coffee
consumption is significantly associated with a decreased risk of postmenopausal cancer. Increasing
coffee consumption by four cups per day was associated with a 20% reduction in endometrial cancer
risk (relative risk (RR) 0.80; 95% confidence interval (CI) 0.72 to 0.89) and with a 24% reduction
in postmenopausal cancer risk (RR 0.76; 95% CI 0.69 to 0.83). Conclusions: Our findings suggest
that increased coffee consumption is associated with decreased risk of endometrial cancer, and this
association is observed also for postmenopausal cancer.
Keywords: coffee; caffeine; postmenopausal; endometrial cancer; prospective cohort; meta-analysis
1. Introduction
Endometrial cancer is the third most common female cancer, after breast cancer and cervical
cancer: in 2012, worldwide, there were over 1.2 million women with a diagnosis of endometrial
cancer made in the previous 5 years. Similarly, in Europe there were 370,000 women with the same
diagnosis [1]. The burden of non-communicable diseases, including cancers, has been associated
with dietary habits, such as the consumption of fibers, sugar, saturated fatty acids, and trans fatty
acids [2–4]. Among others, coffee consumption has also been shown to potentially affect human
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health [5]. Moderate coffee consumption has been suggested to improve metabolic health and to
decrease the risk of mortality [6,7]. Regarding cancer risk, coffee consumption has been associated with
decreased risk of liver [8], prostate [9], pancreatic [10], and colon cancer [11], suggesting a potential role
of coffee in cancer prevention. Coffee is composed of a variety of compounds, including polyphenols,
diterpenes and melanoidins, that have been reported to modulate anti-inflammatory and anti-oxidant
body responses, which may explain the potential beneficial effects of coffee in cancer prevention [12,13].
A decreased risk of endometrial cancer in women who regularly drink coffee has been documented
in retrospective and prospective studies: Je and Giovannucci performed a meta-analysis including
10 case-control and 6 cohort studies and found a significant inverse association of endometrial
cancer with coffee consumption in the highest versus the lowest category of coffee intake [14]. The
dose–response analysis showed a decrease of 8% in the risk of endometrial cancer for an increment
of one cup of coffee per day [14]. Similar conclusions were reported by Zhou and colleagues in
a meta-analysis of prospective studies: they found a significant reduction of endometrial cancer risk
associated with increased coffee consumption, with a linear dose–response relationship [15]. Significant
results were obtained also in the meta-analysis of Yang and colleagues, who estimated a decreased
risk of endometrial cancer of about 10% for every additional daily cup of coffee [16]. Results are
promising but evidence is not yet conclusive, especially regarding specific population subgroups (e.g.,
in relation to body mass index (BMI), age, geographic place of residence, and ethnicity); in light of
the high worldwide consumption of coffee, further research is needed [17,18]. Moreover, new cohort
studies have been published, and some overlapping cohorts were not considered in the previous
meta-analyses [19]. Thus, the aim of this study was to update the current evidence on the association
between coffee intake and risk of endometrial cancer, providing insights on potential effect modifiers
or confounding factors, including the BMI and the menopausal status.
2. Methods
We followed the Meta-Analysis of Observational Studies in Epidemiology (MOOSE) protocols
throughout the design, execution, analysis, and reporting of the current meta-analysis (Supplementary
Table S1) [20].
2.1. Search Strategy
We conducted a comprehensive literature search using two medical databases, namely, PubMed
(http://www.ncbi.nlm.nih.gov/pubmed/) and EMBASE (http://www.embase.com/); the databases
were screened from the earliest available online indexing year up to March 2017, with English-language
restriction. We included the following search terms: (coffee OR caffeine OR beverages OR diet Or dietary)
AND (endometrial OR endometrium) AND (cancer OR carcinoma OR neoplasm) (Supplementary Table S2).
Two authors evaluated independently the pertinence of the retrieved studies and obtained full texts of
the relevant ones. We limited our search to prospective cohort studies that evaluated the association
between dietary coffee intake and the risk of endometrial cancer in the overall female population.
Studies were included if they provided any of the following risk estimates: relative risks (RRs) or
hazard ratios (HRs). We excluded studies that reported insufficient statistics or insufficient coffee
consumption categories (less than three). Among the included manuscripts, all references were also
examined in order to maximize the number of relevant studies through the addition of studies not
previously identified. When duplicate publications from the same study were identified, we chose the
report that provided the largest number of cases (or the entire cohort), or the longest follow-up for
each endpoint of interest. Full texts of potentially relevant articles were assessed independently for
eligibility by two different authors.
2.2. Data Extraction
A standardized extraction form was used to extract data from each study included in the
meta-analysis. The following information was collected: (1) first author name; (2) year of publication;
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(3) study cohort name; (4) country; (5) number of participants; (6) sex of participants; (7) age range of
the study population at baseline; (8) categories of consumption; (9) follow-up period; (10) endpoints
and cases; (11) distributions of cases and person-years, RRs, HRs, and 95% CIs (confidence interval) for
all categories of exposure; (12) covariates used in adjustments. Two authors independently performed
such process, and discrepancies were discussed and resolved by consensus. Each study was critically
appraised through the use of a quality scale, namely, the Newcastle-Ottawa Quality Assessment
Scale [21], which consists of three variables of quality as follows: selection (4 points), comparability
(2 points), and outcome (3 points), for a total score of 9 points (9 representing the highest quality).
2.3. Statistical Analysis
In this meta-analysis, HRs were deemed equivalent to relative risks (RRs) [22]. For each
study, extracted statistical estimates were RRs and HRs with 95% CI for all categories of exposure.
Random-effects models were used to calculate pooled RRs with 95% CI for the highest versus the
lowest categories of exposure (such analysis aimed to assess the presence of a relationship between
coffee intake and risk of endometrial cancer). In performing such analysis, for each study, we used the
risk estimate derived from the most fully adjusted models (analysis of the pooled RR). Heterogeneity
was assessed using the Q test and I2 statistic. The level of significance was set equal to 0.10 for the Q test.
The I2 statistic explains the amount of total variation that could be attributed to heterogeneity. I2 values
≤25%, 25–50%, 50–75%, and >75% indicated no, small, moderate, and significant heterogeneity,
respectively. To evaluate the stability of the results and potential sources of heterogeneity, a sensitivity
analysis by exclusion of one study at a time was performed. Moreover, a subgroup analysis was
performed in order to check for potential sources of heterogeneity according to the geographical
area. To test for potential confounders and effect modifiers, other subgroup analyses were performed
(by menopausal status, receptor status, BMI, smoking status, and coffee type). The publication bias
was evaluated by a visual investigation of the funnel plots for potential asymmetry.
To better explore the relationship between exposure and outcome, a dose–response meta-analysis
was performed (a dose–response analysis was preferred over other designs, e.g., meta-regression,
to better compare our results with previous studies and to better draft potential recommendations
whether evidence would support the present findings). Extracted data were stratified by the level of
coffee intake, and distributions of cases and person-years (when available), and RRs or HRs with 95%
CIs for ≥3 exposure categories were included. The median or mean intake of coffee in each category
was assigned to the corresponding RR or HR with the 95% CI for each study. If coffee consumption
was reported in a range of intake, we used the midpoint of the range. Similarly, when the highest
category was open-ended, we assumed that the width of the category would be the same as the
adjacent category. In the case of an open-ended lowest category, we clearly set the lower boundary
to zero. Two-stage random-effects dose–response meta-analysis was performed to examine linear
and non-linear relationship between coffee intake and risk of endometrial cancer. In the first stage,
the method of Greenland and Longnecker (generalized least-squares, GLS) was used to calculate
study-specific coefficients on the basis of results across categories of coffee intake, taking into account
the correlation within each set of retrieved RRs and HRs [23,24]. Through the use of restricted cubic
splines with three knots at fixed percentiles (25%, 50%, and 75%) of the distributions, non-linear
dose–response analyses were modelled [25], and the coefficients (that had been estimated within
each study by performing random-effects meta-analysis) were combined. To estimate the relative
risks, we used the method of DerSimonian and Laird in linear dose–response meta-analyses, and the
multivariate extension of the method of moments in non-linear dose–response meta-analyses. We
calculated a p-value for non-linearity by testing the coefficient of the second spline as equal to zero.
We performed all analyses with R software version 3.0.3 (Development Core Team, Vienna, Austria).
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3. Results
3.1. Study Characteristics
The search identified 598 studies, of which 511 were excluded after reviewing the title, and 70 on
the basis of the abstract (Figure 1). Of the 17 publications selected, five were excluded for the following
reasons: (1) the article did not provide risk measurements with confidence intervals; (2) the article
did not have a prospective design; (3) the article provided data only on genetic polymorphism. For
the analysis on the association between coffee consumption and endometrial cancer risk, 12 studies
were eligible [16,26–36]. Two cohorts, NOWAC and VIP [27,33], were excluded from the main analysis
because part of theirs cases are included in the multicenter study EPIC [32]. However, an alternative
analysis was performed by including these cohorts and excluding the EPIC study. One article was
used only for subgroup analysis [31]. Studies eligible for the main analysis comprised 1,404,541
participants and 10,548 endometrial cancer cases. The main characteristics of the studies included in
the meta-analysis are described in Table 1. Seven studies provided relative risk measurements for the
postmenopausal [26–31,35] status, and two for the premenopausal status [27,31]. Five studies were
conducted in the USA [28–31,35], five in Europe [16,26,27,33,36], one in Asia [34], and one on a cohort
from Europe and North America [32]. The follow-up in prospective cohort studies ranged from about
6 to 26 years, and the age range at study baseline was between 25 and 74 years (with almost all studies
covering the age range between 40 and 60 years).
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Table 1. Characteristics of the studies included in the meta-analysis.
Author, Year Cohort Name,Country Years of Study, Follow-Up Cases; Total Population Age Range Adjustments
Shimazu, 2008 JPHC, Japan 1990–2005, 15 years(maximum) 117; 53,724 40–59 years
Age, study area, BMI (body mass index), menopausal status, age at menopause
for postmenopausal women, parity, use of exogenous female hormones, smoking
status, green vegetable consumption, beef consumption, pork consumption, and
green tea consumption.
Friberg, 2009 SMC, Sweden 1992–2007, 17.6 years (mean) 677; 60,634 40–76 years Age, BMI, smoking.
Nilsson, 2010 VIP, Sweden 1985–2007, 6 years (median) 108; 32,178 30–60 years Age, sex, BMI, smoking, education, recreational physical activity.
Giri, 2011 WHI, USA 1993–2005, 7.5 years (average) 427; 45,696 50–79 years Age, ethnicity, unopposed estrogen use, progestin + estrogen use, smoking, BMI.
Je, 2011 NHS, USA 1980–2006, 26 years(maximum) 672; 67,470 34–59 years
Age, BMI, age at menopause, age at menarche, parity and age at last birth,
duration of oral contraceptive use, postmenopausal hormone use, pack-years of
smoking, alcohol intake, and total energy intake, tea analysis.
Gunter, 2011 NIH-AARP, USA 1995–2006, 9.3 years (mean) 1486; 111,429 50–71 years
Age, smoking, BMI, age at menarche, age at first child’s birth, parity, age at
menopause, HT (hormonal therapy) use, oral contraceptive use, diabetes and
physical activity.
Ucella, 2013 IWHS, USA 1986–2005, 20 years(maximum) 542; 23,356 55–69 years
Age, diabetes, duration of HT use, hypertension, age at menarche, age at
menopause, BMI, waist-to-hip ratio, smoking status, pack years of smoking, total
energy and alcohol use.
Gavrilyuk, 2011 NOWAC, Norway 1991–2007, 10.9 (average) 462; 97,926 30–70 years Parity, smoking status, BMI, duration of OC (oral contracception) and HRT use.
Weiderpass, 2014 WLH, Sweden 1991–2009, 18 years(maximum) 144; 42,270 30-49 years
Age, education, duration of hormonal contraceptive use, parity, duration of
breastfeeding, smoking status and number of cigarettes/day, menopausal status,
BMI, and diabetes mellitus.
Merritt, 2015 EPIC, Multicentre;NHS/NHSII USA
EPIC 1992-NA, 11 years
(mean); NHS 1976–2010,
25 years (mean); NHSII
1989–2011, 25 years (mean)
EPIC 1303; 301,107;
NHS/NHSII 1531; 155,406
EPIC 25–70 years;
NHS 30–55 years;
NHSII 25–42 years
BMI, total energy intake, smoking status, age at menarche, oral contraceptive use,
a combined variable for menopausal status and postmenopausal hormone (PMH)
use, parity, and was stratified by the age of recruitment, and the study centre.
Owen Yang, 2015 MWS, UK 1996–2001, 9.3 years (average) 4067; 560,356 ~60 years (mean)
Age, region, socioeconomic status, height, age at menarche, parity, duration of
oral contraceptive use, age and status of menopause at study baseline, duration of
hormone therapy for menopause, BMI, smoking, alcohol consumption, strenuous
exercise, tea consumption, and other nonalcohol fluid intake.
Hashibe, 2015 PLCO, USA 1992–2011, 13 years(maximum) 254; 50,563 55–74 years
Age, sex, race, education, smoking status, smoking frequency, smoking duration,
time since stopping smoking for past smokers, and drinking frequency.
Abbreviations: EPIC (European Prospective Investigation into Cancer and Nutrition); IWHS (Iowa Women’s Health Study); JPHC (Japan Public Health Center-based Prospective Study);
NHS (The Nurses’ Health Study); MWS (Million Women Study); NIH-AARP (NIH-AARP Diet and Health Study); NOWAC (The Norwegian Women and Cancer study); PLCO
(Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial); SMC (The Swedish Mammography Cohort); WHI (Women’s Health Initiative); WLH (Women’s Lifestyle and Health); VIP
(Västerbotten intervention project cohort).
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3.2. Summary Relative Risk for Highest vs. Lowest Category of Coffee Consumption
The summary Relative Risk (RR) of endometrial cancer for the highest versus the lowest category
of coffee consumption was RR = 0.79, 95% CI: 0.73, 0.87, with small heterogeneity I2 = 28%, p = 0.19,
(Figure 2); no publication bias was found after a visual inspection of the funnel plot (Supplementary
Figure S1). When we performed the alternative analysis that included the NOWAC and VIP cohorts
instead of the EPIC study (used in the main analysis), the RR was even lower and equal to 0.73 (95% CI:
0.64, 0.84), with moderate heterogeneity (I2 = 44%, p = 0.0375).
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Subgroup/Additional Analysis No. of Datasets RR (95% CI) I2 Pheterogeneity
Total 10 0.79 (0.73, 0.87) 28% 0.19
Geographical area
North A erica 5 0.75 (0.67, 0.84) 6% 0.37
Europe 4 0.84 (0.74, 0.94) 29% 0.24
Asia 1 0.97 (0.56, 1.68) NA NA
Menopausal status
Postmenopausal 7 0.70 (0.63, 0.78) 0% 0.60
Premenopausal 2 0.76 (0.49, 1.19) 16% 0.27
Coffee type
Caffeinated 4 0.65 (0.50, 0.85) 64% 0.04
Decaffeinated 4 0.76 (0.62, 0.93) 0% 0.72
BMI
<25 kg/m2 7 0.99 (0.86, 1.14) 0% 0.58
>25 kg/m2 7 0.79 (0.61, 1.01) 66% 0.004
>30 k m2 5 0.75 (0.63, 0.88) 22% 0.27
Smoking status
Never smoker 8 0.78 (0.68, 0.88) 7% 0.38
Ever smoker (former/current) 8 0.74 (0.57, 0.98) 68% 0.003
Adjusted for smoking
No 0 NA NA NA
Yes 10 0.79 (0.73, 0.87) 28% 0.19
Adjusted for BMI
No 1 0.69 (0.52, 0.91) NA NA
Yes 9 0.80 (0.74, 0.88) 27% 0.20
Adjusted for education
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Table 2. Cont.
Subgroup/Additional Analysis No. of Datasets RR (95% CI) I2 Pheterogeneity
No 8 0.81 (0.74, 0.89) 30% 0.19
Yes 2 0.68 (0.53, 0.87) 0% 0.80
Adjusted for alcohol intake
No 8 0.77 (0.71, 0.84) 0% 0.56
Yes 2 0.85 (0.67, 1.07) 52% 0.15
When taking into account the menopausal status, a significant decrease in the risk of endometrial
cancer (RR = 0.70, 95% CI: 0.63, 0.78; I2 = 0%, p = 0.60) was found for postmenopausal women, but
not for premenopausal women (RR = 0.76 95% CI: 0.49, 1.19; I2 = 16%, p = 0.27). No differences were
observed between ever-smokers and non-smokers, i.e., in both subgroups the risk was significantly
reduced for the highest category of coffee consumption compared to lowest category (RR = 0.78, 95%
CI: 0.68, 0.88 for non-smokers, and RR = 0.74, 95% CI: 0.57, 0.98 for ever-smokers, respectively, Table 2).
Finally, the analysis of the highest versus the lowest category of coffee consumption according to body
mass index (BMI) categories showed a significant decrease in the risk of endometrial cancer among the
obese (BMI > 30 kg/m2) women (RR = 0.75, 95% CI: 0.63, 0.88).
3.3. Dose–Response Meta-Analysis
Nine studies [16,26,28–30,32,34–36] were eligible for dose–response meta-analysis of prospective
cohort studies on coffee consumption and endometrial cancer risk. Six studies [26–31] provided risk
estimates for postmenopausal women only. In both the non-linear and the linear dose–response
meta-analyses, a significant association between coffee consumption and endometrial cancer risk was
found (Figure 3, Table 3). Compared to no coffee consumption, the pooled relative risks for endometrial
cancer were: 0.95, 95% CI: 0.92, 0.97, for one cup/day; 0.90, 95% CI: 0.85, 0.94, for two cups/day; 0.85,
95% CI: 0.78, 0.92, for three cups/day; 0.80, 95% CI: 0.72, 0.89, for four cups/day; 0.76, 95% CI: 0.67,
0.86, for five cups/day; 0.72, 95% CI: 0.61, 0.84, for six cups/day; 0.68, 95% CI: 0.57, 0.81, for seven
cups/day. Two cohorts, NOWAC and VIP, were excluded from the main analysis, as part of theirs
cases are included in the multicentre study EPIC. However, an alternative analysis was performed
by including these cohorts and excluding the EPIC study, confirming the results of the main analysis
(Supplementary Table S3). Finally, the association between coffee intake and endometrial cancer was
stronger when taking into consideration postmenopausal women.
Table 3. Dose–response meta-analysis of prospective cohort studies on coffee consumption and
endometrial cancer risk.
No. of Datasets
(No. of Studies)
Coffee Intake (Cups/Day)
I2(%) Pheterogeneity Pnon-linearity
0 1 2 3 4 5 6 7
Total analysis
Non-linear 11 (9) Ref.
0.91
(0.85,
0.97)
0.85
(0.76,
0.94)
0.81
(0.73,
0.91)
0.79
(0.70,
0.89)
0.76
(0.67,
0.87)
0.74
(0.64,
0.86)
0.72
(0.61,
0.85)
30.98 0.09 0.09
Linear 11 (9) Ref.
0.95
(0.92,
0.97)
0.90
(0.85,
0.94)
0.85
(0.78,
0.92)
0.80
(0.72,
0.89)
0.76
(0.67,
0.86)
0.72
(0.61,
0.84)
0.68
(0.57,
0.81)
59.21 0.01 NA
Postmenopausal
Non-linear 7 (6) Ref.
0.92
(0.83,
1.01)
0.85
(0.73,
0.99)
0.80
(0.69,
0.92)
0.75
(0.65,
0.87)
0.71
(0.61,
0.83)
0.67
(0.56,
0.79)
0.63
(0.52,
0.76)
0 0.64 0.67
Linear 7 (6) Ref.
0.93
(0.91,
0.95)
0.87
(0.83,
0.91)
0.81
(0.76,
0.87)
0.76
(0.69,
0.83)
0.71
(0.63,
0.79)
0.66
(0.58,
0.76)
0.62
(0.53,
0.72)
0 0.46 NA
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4. Discussion
The present meta-analysis, including 12 prospective cohort studies, showed that coffee
consumption is associated with a lower risk of endometrial cancer; such association was stronger for
postmenopausal endometrial ca cer and in obese w m n (BMI > 30).
Various meta-analy es on the asso iat on of coffee consumption an endometri l cancer risk
have been conducted so far: for instance, in 2011 Je a d Giovannucci [14] documented an inverse
dose–response association, with a geographical gradient (stronger association in Japan, followed by the
USA and then Europe). Subgroup analyses were later published in 2015 by Yang and colleagues [16]
and by Zhou and colleagues [15]: both groups limited their analyses to prospective studies and found
a linear inverse association. The first research group found some evidence of heterogeneity among
BMI subgroups (overweight women, with a BMI higher than 25, showed a more pronounced inverse
association than women with a lower BMI). The second group confirmed these results and pointed out
a similar pattern for women without a history of hormone therapy, while documenting no differences
with respect to study location, smoking status, and menopausal status. Compared to the previous
literature, our results, especially on subgroup analyses for postmenopausal status and BMI (overweight
vs obese), are in line with the reported observations, yet provide original findings.
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Coffee constituents have been associated with several biological mechanisms related to
carcinogenesis, both in vitro and in vivo. These mechanisms include: DNA methylation, oxidative
damage, activation of proto-oncogenes and inactivation of onco-suppressor genes, loss of apoptosis
and growth control, and induction of angiogenesis [37,38]. Active coffee constituents that have been
identified include not only caffeine (mainly known for its ability to increase blood pressure and for its
psychostimulatory and diuretic properties) [39], but also polyphenols (e.g., chlorogenic acids, which
produce catechins, caffeic, ferulic and coumaric acids), lipids in the form of diterpenes (e.g., cafestol
and kahweol), melanoidins, and trigonelline [40,41]. There is evidence that dietary polyphenols might
be associated with decreased mortality and cancer risk, and may be the mediators of the potential
effects of coffee on cancer prevention [42,43].
With particular referral to female reproductive cancers, several mechanisms have been proposed:
for instance, caffeine and coffee intake have been positively associated to sex hormone-binding globulin
(SHBG) in postmenopausal women [44]. SHBG is the major carrier of estrogens and testosterone,
thus lowering the circulating levels of free hormones; the positive relationship between coffee or
caffeine intake and SHBG has been proved in many studies [45,46]. Another possible mechanism
resulting in lower levels of circulating estrogens after coffee intake is through the inhibition of the
enzyme converting androgens into estrogens, i.e., CYP19 or aromatase [44]. A low level of estrogens
is considered a protective factor against endometrial cancers acting through the down-regulation of
endometrial proliferation [45], and the inverse association between coffee or caffeine consumption and
estrogens has been widely documented [47,48].
Additional effects of coffee and caffeine intake on hormonal functions have been seen in improved
insulin sensitivity as a result of the stimulation of insulin-mediated uptake of glucose [49]. Coffee
could therefore have a protective role against type 2 diabetes development: most epidemiological
studies have documented an inverse association between the intake of caffeinated coffee, decaffeinated
coffee, and caffeine and type 2 diabetes in a dose–response manner compared with no or infrequent
coffee consumption [50]. In turn, type 2 diabetes has been associated with an increased risk of
endometrial cancer, and more specifically with an increased risk of type 1 endometrioid endometrial
adenocarcinoma [51]. In recent epidemiological studies, such risk has been associated not only with
insulin resistance and diabetes, but also with the metabolic syndrome that is characterized by the
coexistence of various factors, such as abdominal obesity, low levels of high density lipoprotein,
elevated levels of triglycerides and low levels of density lipoprotein, hypertension, and insulin
resistance [52,53].
As already pointed out, we observed a stronger association between coffee consumption and
endometrial cancer in women with high BMI (above 30) compared with women with a BMI of 25
or lower. Overweight and obesity have been associated with the development of cancers [54], and
various mechanisms have been proposed, including: (i) chronic inflammation and oxidative stress;
(ii) cross-talk between tumor cells and surrounding adipocytes; (iii) migration of adipose stromal cells;
(iv) obesity-induced hypoxia; (v) genetic susceptibility; and (vi) immunological dysfunctions [55].
In several studies, coffee intake has been inversely associated with metabolic syndrome [56–66].
Metabolic risk factors, such as obesity, impaired glucose tolerance, dyslipidemia, and hypertension
have been linked to elevated systemic inflammation and oxidative stress. Thus, impaired metabolism
may induce inflammation and oxidative stress, which in turn may lead to carcinogenic transformation.
Within these pathways, four main components have been identified: insulin, insulin-like growth
factor-I, sex steroids, and adipokines, and coffee consumption has been associated, directly or
indirectly, with most of them [55]. For instance, an in vitro study showed that exposure to coffee
reduced the accumulation of lipids inhibiting adipocytic differentiation [67]. In animal models, coffee
consumption has been related to changes in transcription factors and lipogenesis-related proteins, and,
in epidemiological studies, decreased body weight and decreased visceral fat, in relation to coffee
consumption, have been observed [68].
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The present meta-analysis has some limitations. First, despite we provided insights on underrated
factors potentially affecting the association between coffee consumption and endometrial cancer risk,
other variables (such as the type of coffee seeds, the roasting method, and the type of preparation)
remained largely unexplored. Second, we cannot rule out the possibility of changes in dietary habits
(i.e., increased or decreased consumption of coffee) over time, leading to the risk of reverse causation
in the event that an individual changed coffee intake due to a newly diagnosed medical condition.
5. Conclusions
In conclusions, our findings suggest that increased coffee consumption is associated with
decreased risk of endometrial cancer, especially in postmenopausal, obese women.
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